Duncan-Williams Previews 2Q Earnings for Vascular Solutions

Loading...
Loading...
Duncan-Williams has published a research report on Vascular Solutions
VASC
previewing earnings for the second quarter. In the report, Duncan-Williams wrote, "Our Q2:11 Catheters revenue estimate is $13.5 million. This represents approximately 31% growth compared to the same period last year. Catheters revenue represents approximately 60% of total revenue for Q2:11. We look for sales of the GuideLiner catheter and the Pronto catheter to drive revenue growth in Q2:11. We estimate 2011 Catheters revenue of approximately $52.6 million. This represents 25% growth compared to 2010." Duncan-Williams rated Vascular Solutions a BUY with a price target of $15.00. Vascular Solutions closed Thursday at $13.35.
Market News and Data brought to you by Benzinga APIs
Posted In: Analyst ColorAnalyst RatingsDuncan-WilliamsHealth CareHealth Care SuppliesVascular Solutions
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...